Compare CENT & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CENT | SYRE |
|---|---|---|
| Founded | 1955 | 2013 |
| Country | United States | United States |
| Employees | 6000 | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | N/A | 2015 |
| Metric | CENT | SYRE |
|---|---|---|
| Price | $36.25 | $43.98 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $50.00 | ★ $55.57 |
| AVG Volume (30 Days) | 58.2K | ★ 672.7K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.60 | N/A |
| Revenue Next Year | $2.04 | N/A |
| P/E Ratio | $15.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.77 | $10.91 |
| 52 Week High | $41.25 | $45.76 |
| Indicator | CENT | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 41.74 | 65.40 |
| Support Level | $34.52 | $15.01 |
| Resistance Level | $36.36 | $45.76 |
| Average True Range (ATR) | 0.84 | 2.18 |
| MACD | -0.40 | -0.09 |
| Stochastic Oscillator | 2.58 | 80.37 |
Central Garden & Pet Co offers solutions that support healthier pets, greener lawns, and thriving gardens. Its products include dog and cat treats, chews, toys, beds, containment, grooming supplies, aquatics, small animal and bird supplies, equine and livestock products, insect control solutions, grass seed, wild bird feed, fertilizers, pest controls, live plants, and packet seeds, sold under brands such as Aqueon, Nylabone, Kaytee, Farnam, Pennington, Ferry Morse, Amdro, and Sevin. The company operates through two segments, Pet and Garden, and sells through retailers, independent stores, eCommerce channels, and professional markets. It has sales and distribution operations mainly across the United States, with additional facilities in Canada and Mexico.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.